Recombinant tissue plasminogen activator to declot dialysis fistulas

被引:0
|
作者
Boobes, Y
AlHassan, H
Neglen, P
Obeid, K
Denour, N
机构
关键词
hemodialysis; rt-PA; thrombolysis; vascular access;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background, Thrombosis is the most common complication of hemodialysis access, Few reports are available concerning the use of recombinant tissue plasminogen activator (rt-PA) to declot an arterio-venous (A-V) access, This report describes the use of rt-PA for this purpose in 17 A-V accesses, Methods, The rt-PA was infused manually using a small catheter directly into the A-V access in 10-mg doses at 1-2 hour intervals, to a maximum dose of 40 mg, The procedure was followed by angiography, through the same catheter, Results. One fistula could not be cannulated, and in three the lysis of the clot failed, The other 13 cases (3 fistulas, and 10 grafts 81%) had successful lysis with return of bruit and thrill, Most patients had dialysis the next day using the declotted A-V access, Angiogram detected stenosis in six patients and surgical revision was done 1-8 days after the treatment, In the other seven patients no organic lesions were found, and six of them have a functioning A-V access 50-395 days after the lysis, Only 10-20 mg of rt-PA was needed in 60% of the cases, No major complication occurred; minor local bleeding was noted in five patients (5/16, 31%), Conclusion, rt-PA can be considered safe, effective and fast for declotting thrombosed arteriovenous fistulas.
引用
收藏
页码:107 / 110
页数:4
相关论文
共 50 条
  • [31] Recombinant tissue plasminogen activator infusion for hemodialysis catheter clearance
    Oluwatoyin F. Bamgbola
    Marcela del Rio
    Frederick J. Kaskel
    Joseph T. Flynn
    Pediatric Nephrology, 2005, 20 : 989 - 993
  • [32] EXPERIMENTAL ADHESION PROPHYLAXIS WITH RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR
    VIPOND, MN
    WHAWELL, SA
    SCOTTCOOMBES, DM
    THOMPSON, JN
    DUDLEY, HAF
    ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 1994, 76 (06) : 412 - 415
  • [33] Resurrection of an ALT flap with recombinant tissue plasminogen activator and heparin
    Nikkhah D.
    Green B.
    Sapountzis S.
    Gilleard O.
    Sidhu A.
    Blackburn A.
    European Journal of Plastic Surgery, 2016, 39 (3) : 221 - 224
  • [34] RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR INDUCES COMPLEMENT ACTIVATION
    BENNETT, WR
    BOLLI, R
    RAIZNER, A
    PRATT, C
    MIGLIORE, P
    YOUNG, J
    YAWN, D
    ROBERTS, R
    CLINICAL RESEARCH, 1986, 34 (02): : A282 - A282
  • [35] Administration of Recombinant Tissue Plasminogen Activator for Sulcal Artery Syndrome
    Lawson, Eric C.
    Hu, Ranliang
    Silver, Michael
    Greene, James G.
    NEUROLOGY-CLINICAL PRACTICE, 2021, 11 (06) : E901 - E903
  • [36] Expanding Recombinant Tissue Plasminogen Activator Time Window Is Premature
    Alper, Brian S.
    Brown, Cynthia B.
    STROKE, 2009, 40 (11) : E632 - E632
  • [37] CLEARANCE OF A NOVEL RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR IN RABBITS
    FU, KP
    LEE, S
    HETZEL, N
    FENICHEL, R
    HUM, HW
    SPETH, J
    KALYAN, N
    HUNG, PP
    THROMBOSIS RESEARCH, 1988, 50 (05) : 679 - 685
  • [38] Changes in blood viscosity with the recombinant tissue plasminogen activator alteplase
    Hitosugi, Masahito
    Omura, Kazunobu
    Yufu, Tetsuo
    Kido, Masahito
    Niwa, Munehiro
    Nagai, Toshiaki
    Tokudome, Shogo
    THROMBOSIS RESEARCH, 2007, 120 (03) : 447 - 450
  • [39] Recombinant tissue plasminogen activator following paediatric cataract surgery
    Mehta, JS
    Adams, GGW
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2000, 84 (09) : 983 - 986
  • [40] Intraocular fibrinolysis with recombinant tissue plasminogen activator - A multicentre trial
    Steinkamp, GWK
    Klais, C
    Hattenbach, LO
    Ohrloff, C
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1997, 38 (04) : 2555 - 2555